
Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
BiotechTV - News
00:00
Monte Rosa’s Expanding Clinical Pipeline
Markus Warmuth previews upcoming trials for partnered autoimmune programs, oncology asset MRT-2359, and new CDK2-Cyclin E1 programs entering the clinic.
Play episode from 18:26
Transcript


